RAPT Therapeutics Stock Soars As Atopic Dermatitis Candidate Shows Promising Action In Early-Stage Study

RAPT Therapeutics Inc RAPT has announced topline results from its Phase 1b trial of RPT193 as monotherapy for moderate-to-severe atopic dermatitis (AD).
After four weeks of treatment, patients with moderate-to-severe AD who received RPT193 showed a 36.3% improvement from baseline in the Eczema disease severity score, compared to 17.0% in the placebo group.
Notably, in the two weeks following the end of treatment, the RPT193 group showed continued improvement and further separation from placebo with a 53.2% improvement in EASI at the six-week time point compared to 9.6% in the placebo group.
42.9% of patients treated with RPT193 achieved a 50% improvement in EASI score (EASI-50) compared with 10.0% in the placebo group.
45.0% of patients treated with RPT193 achieved at least a four-point reduction in the pruritus (itch) score, compared with 22.2% in the placebo group.
RPT193 was well tolerated in the Phase 1b study. No serious adverse events were reported, and all adverse events reported were mild or moderate in intensity.
The company plans to initiate a dose-ranging Phase 2b study in moderate-to-severe AD and a Phase 2a study in asthma.
Price Action: RAPT shares are up 67.3% at $31.06 during the premarket session on the last check Monday.